title: Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
abstract: The long-term evolution of familial myeloproliferative neoplasms was studied in 93 families with 227 subjects including 97 with polycythemia vera (PV), 105 essential thrombocythemia (ET), 14 primary myelofibrosis (PMF) and 11 chronic myeloid leukemia (CML). In PV patients, with 12years of median follow-up, overall survival was 83% at 10years and 37% at 20years. A high JAK2(V617F) allele burden was correlated with the transformation to myelofibrosis (p<0.0001), but not with the transformation to acute leukemia. Among the 105 ET, with 8years of median follow-up, overall survival was 83% at 10years and 57% at 20years. Progression to acute leukemia and progression to myelofibrosis were 10% and 13%. There was a trend toward a more frequent evolution to myelofibrosis when the JAK2(V617F) mutated allele burden was >50% (p=0.09), but not to AML. Hematologic transformation of the MPN was responsible for 69% of the deaths, cerebral stroke for 7% and 4% died of myocardial infarction. Eleven JAK2(V617F) mutated patients developed 13 deep splanchnic thromboses in PV and ET. Finally whereas patients with familial PV and ET have a comparable prognosis to non-familial MPN, the JAK2(V617F) mutation was associated with a more frequent occurrence of thrombosis in the entire population.
authors: Department of Hematology, Assistance Publique-Hopitaux de Paris (AP-HP) Saint-Antoine, Universite Pierre et Marie Curie, Paris, France.
authors: Sandra
authors: S
authors: Malak
authors: Myriam
authors: M
authors: Labopin
authors: Cecile
authors: C
authors: Saint-Martin
authors: Christine
authors: C
authors: Bellanne-Chantelot
authors: Albert
authors: A
authors: Najman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005787:Gene Frequency; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000235:genetics* / Q000401:mortality; D008017:Life Expectancy; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D011087:Polycythemia Vera / Q000150:complications / Q000235:genetics* / Q000401:mortality; D055728:Primary Myelofibrosis / Q000150:complications / Q000235:genetics* / Q000401:mortality; D016019:Survival Analysis; D013920:Thrombocythemia, Essential / Q000150:complications / Q000235:genetics* / Q000401:mortality; D013927:Thrombosis / Q000209:etiology / Q000235:genetics* / Q000401:mortality; D055815:Young Adult
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2